[{"id":"ab6d3749-1aae-4800-9afd-f5306727287f","acronym":"PLACARD","url":"https://clinicaltrials.gov/study/NCT03873025","created_at":"2021-01-18T19:05:49.079Z","updated_at":"2025-02-25T16:08:58.883Z","phase":"Phase 1/2","brief_title":"A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03873025 - PLACARD","lead_sponsor":"University College, London","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zabinostat (CXD101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2021-08-17"}]